stockrowExelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
Follow EXEL
Alert me
Exelixis, Inc. (EXEL) Net income
Exelixis, Inc.'s net income for fiscal 2025 was $782.6M, up 50.1% from $521.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was $885.1M. Over the past ten years it has ranged from −$161.7M (fiscal 2015) to $782.6M (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 3 consecutive fiscal years. Exelixis, Inc. ranks 9th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $782.6M | 50.13% |
| FY2024 | $521.3M | 150.89% |
| FY2023 | $207.8M | 13.98% |
| FY2022 | $182.3M | (21.11%) |
| FY2021 | $231.1M | 106.71% |
| FY2020 | $111.8M | (65.18%) |
| FY2019 | $321.0M | (53.48%) |
| FY2018 | $690.1M | 347.44% |
| FY2017 | $154.2M | — |
| FY2016 | −$70.2M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $218.1M | 2.85% |
| Jun 2026 | $212.1M | 0.75% |
| Mar 2026 | $210.5M | (13.93%) |
| Dec 2025 | $244.5M | 26.32% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | $2.6B |
| EXEL Exelixis, Inc. | $885.1M |
| ASND Ascendis Pharma A/S compare | $865.9M |
| HALO Halozyme Therapeutics, Inc. compare | $485.4M |
| JAZZ Jazz Pharmaceuticals PLC compare | $206.0M |
| BBIO BridgeBio Pharma, Inc. compare | −$577.6M |
| INSM Insmed, Inc. compare | −$605.6M |
| SMMT Summit Therapeutics PLC compare | −$856.1M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.6B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on EXEL
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement